India’s Natco Pharma was hit with a Form 483 by the FDA following an inspection that resulted in eight observations. The citation centered on a lack of cleanliness and sterility of equipment plus ...
Roughly a year after receiving an FDA reprimand at its manufacturing plant in Michigan, Indian drugmaker Piramal Pharma has landed in the regulator’s crosshairs once again. Following an inspection of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback